Adverum Biotechnologies Inc.

8.98-0.0900-0.99%Vol 576.66K1Y Perf -19.01%
Apr 13th, 2021 15:03 DELAYED
BID8.98 ASK8.99
Open9.04 Previous Close9.07
Pre-Market- After-Market-
 - -%  - -
Target Price
23.88 
Analyst Rating
Strong Buy 1.38
Potential %
168.32 
Finscreener Ranking
★★★★     55.37
Insiders Trans % 3/6/12 mo.
11/11/-69 
Value Ranking
★★★★     57.08
Insiders Value % 3/6/12 mo.
27/27/-77 
Growth Ranking
★★★     52.96
Insiders Shares Cnt. % 3/6/12 mo.
40/40/-60 
Income Ranking
 —    -
Market Cap878.21M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
1.26 
Earnings Date
27th May 2021

Today's Price Range

8.759.13

52W Range

8.7526.98

5 Year PE Ratio Range

-7.30-1.30

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.29%
1 Month
-15.00%
3 Months
-20.30%
6 Months
-22.54%
1 Year
-19.01%
3 Years
40.62%
5 Years
69.85%
10 Years
-

TickerPriceChg.Chg.%
ADVM8.98-0.0900-0.99
AAPL134.323.08002.35
GOOG2 271.2116.42000.73
MSFT258.272.36000.92
XOM55.700.20000.36
WFC39.93-0.8400-2.06
JNJ159.58-2.0600-1.27
FB311.740.20000.06
GE13.50-0.0900-0.66
JPM154.88-1.0700-0.69
Financial StrengthValueIndustryS&P 500US Markets
20.60
20.80
0.06
0.07
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-36 120.80
-35 071.60
-13 415.90
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-48.48
-27.54
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.32-0.39-21.88
Q03 2020-0.35-0.3111.43
Q02 2020-0.30-0.36-20.00
Q01 2020-0.27-0.31-14.81
Q04 2019-0.31-0.296.45
Q03 2019-0.27-0.257.41
Q02 2019-0.31-0.2325.81
Q01 2019-0.28-0.2317.86
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.36-12.50Negative
6/2021 QR-0.38-15.15Negative
12/2021 FY-1.64-20.59Negative
12/2022 FY-2.05-40.41Negative
Next Report Date27th May 2021
Estimated EPS Next Report-0.36
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume576.66K
Shares Outstanding97.80M
Trades Count5.08K
Dollar Volume9.19M
Avg. Volume837.23K
Avg. Weekly Volume810.82K
Avg. Monthly Volume862.00K
Avg. Quarterly Volume813.80K

Adverum Biotechnologies Inc. (NASDAQ: ADVM) stock closed at 9.07 per share at the end of the most recent trading day (a -0.11% change compared to the prior day closing price) with a volume of 687.56K shares and market capitalization of 878.21M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 114 people. Adverum Biotechnologies Inc. CEO is Laurent Fischer.

The one-year performance of Adverum Biotechnologies Inc. stock is -19.01%, while year-to-date (YTD) performance is -16.33%. ADVM stock has a five-year performance of 69.85%. Its 52-week range is between 8.75 and 26.98, which gives ADVM stock a 52-week price range ratio of 1.26%

Adverum Biotechnologies Inc. currently has a PE ratio of -7.10, a price-to-book (PB) ratio of 2.19, a price-to-sale (PS) ratio of 4 025.64, a price to cashflow ratio of 242.90, a PEG ratio of 2.32, a ROA of -32.41%, a ROC of -28.74% and a ROE of -37.61%. The company’s profit margin is -%, its EBITDA margin is -35 071.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Adverum Biotechnologies Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.36 for the next earnings report. Adverum Biotechnologies Inc.’s next earnings report date is 27th May 2021.

The consensus rating of Wall Street analysts for Adverum Biotechnologies Inc. is Strong Buy (1.38), with a target price of $23.88, which is +168.32% compared to the current price. The earnings rating for Adverum Biotechnologies Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adverum Biotechnologies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adverum Biotechnologies Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.73, ATR14 : 0.91, CCI20 : -148.84, Chaikin Money Flow : -0.21, MACD : -0.68, Money Flow Index : 38.42, ROC : -1.95, RSI : 41.28, STOCH (14,3) : 8.72, STOCH RSI : 0.85, UO : 30.69, Williams %R : -91.28), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adverum Biotechnologies Inc. in the last 12-months were: Dawn Svoronos (Buy at a value of $200 338), James Scopa (Option Excercise at a value of $302 409), Laurent Fischer (Buy at a value of $297 967), Leone Patterson (Option Excercise at a value of $206 400), Leone Patterson (Sold 124 579 shares of value $2 529 816 ), Mehdi Gasmi (Option Excercise at a value of $912 000), Mehdi Gasmi (Sold 175 604 shares of value $3 786 617 ), Patrick C. Machado (Buy at a value of $214 370), Peter Soparkar (Buy at a value of $99 996)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (75.00 %)
6 (75.00 %)
4 (66.67 %)
Moderate Buy
1 (12.50 %)
1 (12.50 %)
0 (0.00 %)
Hold
1 (12.50 %)
1 (12.50 %)
2 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.38
Strong Buy
1.38
Moderate Buy
1.67

Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. The company is committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye, who currently have limited or burdensome treatment options. Its services are focused on advancing three lead gene therapy programs to address unmet needs in wet age-related macular degeneration and in rare diseases alpha-1 antitrypsin deficiency and hereditary angioedema. Its leading programs include ADVM-022, ADVM-043 and ADVM-053.

CEO: Laurent Fischer

Telephone: +1 650 659-9323

Address: 800 Saginaw Drive, Redwood CIty 94063, CA, US

Number of employees: 114

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

67%33%

Bearish Bullish

60%40%

News

Stocktwits